November 15, 2018 / 12:33 PM / a month ago

United Therapeutics to develop, sell Arena Pharma's hypertension treatment

Nov 15 (Reuters) - United Therapeutics Corp on Thursday signed a deal potentially worth up to $1.2 billion for the rights to develop and sell Arena Pharmaceuticals Inc’s pulmonary arterial hypertension treatment, ralinepag.

The two companies said in a statement the deal for Arena’s late-stage experimental treatment also includes milestone payments of up to $400 million based on certain regulatory events.

Arena will receive low double-digit tiered royalties on annual net sales of ralinepag, the companies said.

Reporting by Aakash Jagadeesh Babu in Bengaluru

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below